Standardized Microbiota Transplant Therapy in Crohn's Disease

Phase 2

Recruiting

• Conditions: Crohn Disease
• Interventions: Biological: MTP-101C; Biological: MTP-101S

• Registration Number: NCT06631586
• Lead Sponsor: University of Minnesota

Brief Summary

Crohn's disease (CD) develops because of a disruption of homeostasis between the gut microbiota and the host immune system resulting in excessive inflammation in the intestinal tract. Current drug therapies for CD are directed at the immune system. The emergence of fecal microbiota transplantation (FMT) for the treatment of recurrent C. difficile infections (rCDI) has opened a frontier of restorative therapies targeting the gut microbiome. This study aims to assess if two forms of encapsulated FMT material (MTP101C and MTP101S) can effectively engraft in the ileum and colon of individuals with CD. This study will also assess how the impact of CD phenotype impacts engraftment. Finally this study will explore symptom and endoscopic changes before and after these two therapies.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2024-10-06
• Study First Submitted QC: 2024-10-07
• Study First Posted: 2024-10-08
• Study Start: 2025-01-15
• Status Verified: 2025-02
• Last Update Submitted: 2025-02-03
• Last Update Posted: 2025-02-04
• Primary Completion: 2029-06-15
• Study Completion: 2029-06-15

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 120

Inclusion Criteria

• Able and willing to provide informed consent.

• 18-89 years of age.

• English speaking.

• Diagnosis of CD based on typical clinical and histologic features.

• Active disease on endoscopy:

  • SES-CD >= 6
  • SES-CD >= 4 for isolated ileal disease

• Current CD therapies are in the maintenance phase of dosing at the time of randomization.

• Any ongoing CD therapy (apart from steroid use) must be at stable doses for 4 weeks prior to randomization and remain stable over study course.

• Steroid use 20mg or less by 5 days prior to randomization.

• Steroid use stipulations:

• Prednisone must be tapered below 20mg after 7 days.

• Any use of budesonide over the study period is allowed although tapering is encouraged.

• Rescue medications: Steroid courses (up to 40mg for two weeks with a planned taper) are allowed at the discretion of the treating provider. Study drug therapy will be stopped on a case-by-case basis on discussion with the participant and treating provider.

• Women who are not post-menopausal (at least 12 months of non-therapy induced amenorrhea) or surgically sterile (e.g., absence of ovaries and/or uterus) must remain abstinent or use a highly effective form of birth control (e.g., oral contraception, transdermal patch, barrier, intrauterine device).

  o Periodic abstinence and early withdraw are not acceptable methods.

• Able to comply with study measures in the opinion of the investigator.

Exclusion Criteria

• Extensive bowel resection: i.e., subtotal colectomy or substantial removal of small bowel where short bowel syndrome could be a concern.

• Documented gastroparesis

• History of pylorus non-preserving gastric surgery, e.g., Roux-en-Y gastric bypass.

• Symptomatic stricture defined as a stricture that:

  • Cannot be traversed by the colonoscope,
  • Requires intervention to be traversed,
  • Is otherwise responsible for the predominant clinical picture, in the opinion of the investigator.

• Presence of ileostomy or colostomy.

• Entero-vesicular fistula (i.e., fistula from bowel to bladder).

• Suspicion of ischemic colitis, radiation colitis or microscopic colitis.

• Diagnosis of ulcerative colitis.

• Active or untreated infection.

• Adenomatous polyps that have not been removed.

• Use of antibiotics within 14-days of randomization.

• Current pregnancy.

• Current breastfeeding or planning to breastfeed over the study period.

• History of anaphylactic food allergies.

• End stage liver disease or cirrhosis.

• Anticipated need for antibiotics over the study period.

• Anticipated surgical procedure over the study period.

• An absolute neutrophil count <500 cell/µL.

• Diagnosis of a primary immunodeficiency.

• Active malignancy requiring the use of chemotherapeutic agent (except for localized non-melanomatous skin cancers).

• Patients receiving active cytotoxic therapy for solid tumors and hematologic malignancies.

• Any solid organ transplant within 6 months of randomization.

• Use of chimeric antigen receptor T-cell therapy or hematopoietic cell transplant within the past 12 months

• Life expectancy >=6 months.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
CD patients randomized to MTP-101C	MTP-101C	-
CD patients randomized to MTP-101S	MTP-101S	-

Primary Outcome Measures

Name	Time	Method
donor microbial engraftment	2months	measured in intestinal ileal biopsies

Secondary Outcome Measures

Name	Time	Method
Changes in ileal microbial composition	2 months	biopsy samples, between baseline and 2 months
Colonic engraftment of donor microbiota	2 months	colonic biopsies
Changes in colonic microbial composition	2 months
Engraftment	2 months	measured by fecal samples over the study period.
Microbial compositional changes	2 months
Changes in clinical symptoms	baseline, 2 months, 6 months	measured by the Crohn's Disease Activity Index (CDAI) at baseline, 2-months, and 6-months.
Endoscopic changes in inflammation	2 months	measured by the Single Endoscopic Score for Crohn's Disease (SES-CD) at baseline and 2-months.
Safety and tolerability of MTT	2 months	measured by the rate of AEs and SAEs.

Trial Locations

Locations (1)

University of Minnesota; 🇺🇸 Minneapolis, Minnesota, United States